Excelimmune specializes in developing recombinant polyclonal antibodies to create novel human therapeutics. Its lead program, Staphguard, is a human recombinant polyclonal antibody (HRPA) candidate against methicillin-resistant Staphylococcus aureus (MRSA). The company uses an antibody screening technology it says can be applied beyond infectious diseases to other pathogenic bacteria, viruses, disease-causing proteins, and cancer. Excelimmune plans to use new capital to advance its infectious disease programs and to expand discovery efforts into new disease targets. The company is led by CEO Quinton Zondervan and was founded to translate its recombinant polyclonal platform into clinical candidates. Financially, the company announced a $12M financing to support these development and discovery plans. Excelimmune develops human recombinant polyclonal antibodies (HRPAs) and is advancing Staphguard, an HRPA candidate targeting MRSA. The company reported positive preclinical results showing 100% survival in a lethal MRSA challenge at ICAAC. Proceeds from the Series B are intended to advance Staphguard toward the clinic, enhance the discovery platform, and complete proof-of-principle for its manufacturing systems. Excelimmune says its polyclonal approach can address complex bacterial antigens and may be applicable to other pathogens and disease areas. Management also reports the company doubled its size over the past year and is pursuing industry collaborations to expand applications of the HRPA technology. Excelimmune was founded in 2006 and is based in Woburn, Mass. Excelimmune develops recombinant polyclonal antibodies as novel human therapeutics. Its lead candidate, Staphguard, is a human recombinant polyclonal antibody (HRPA) targeting methicillin-resistant Staphylococcus aureus (MRSA). The company has completed a pre-clinical mouse study of Staphguard and is partnering with Clinquest to advance development toward an IND filing. Proceeds from its recent financing will be used to continue studies of Staphguard. In September 2009 Excelimmune was awarded an NIH SBIR Phase I grant to develop an HRPA against Clostridium difficile. The company is based in Woburn, Massachusetts.

Total raised

$24M

Funding rounds

3

Latest round

Equity

Latest activity

Dec 2011